Seres Therapeutics, Inc. (MCRB) Shares Active after Upgrade at Zacks Investment Research

Seres Therapeutics, Inc. (NASDAQ: MCRB) shares slid back in value on Tuesday January 17 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a upgraded rating.

Meanwhile, in early trade, the Dow Jones Industrial Average was 47 points lower, or 0.24% to 19838, the S&P 500 fell 7 points, or 0.29% to 2267, while the Nasdaq was down 19 points, or 0.35% to 5554.

Stock Picks and Investing in the Stock Market

Analysts at Zacks Investment Research upgraded shares of Seres Therapeutics, Inc. (NASDAQ: MCRB) from Sell to Hold today. Zacks Investment Research currently has a rating of Hold on the stock. As a means of comparison, a number of other analysts have commented on the stock recently, and the company has earned a consensus one-year price target of $15.43, above the opening price of $10.86, a difference of 14.63 percent. Seres Therapeutics, Inc. stock has a 52-week high of $35.98. Typically, after analysts publish an upgrade report on a stock, they will subsequently issue sporadic revisions, often followed by a price target change.

Yesterday Seres Therapeutics, Inc. (NASDAQ: MCRB) shares last traded at $10.55, a dip of $0.39 from the previous closing price. Opening at $10.86, they fluctuated from $10.50 and $10.86 throughout the day.

Seres Therapeutics, Inc. (NASDAQ: MCRB) currently has a market cap of 425.75M.

Seres Therapeutics, Inc. (NASDAQ: MCRB) Average Daily Trading Volume

The stock’s average daily volume is 271,906 shares out of a total float 20,271,000 and some 16,921 shares crossed the trading desk yesterday, 70 percent lower than the norm. lower than normal. Look for trading volume to pick up in the coming days as investors often use swings in trading volume to identify heavy volume accumulation or distribution by institutional investors.

As with all potential breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have substantial teams of analysts researching thousands of stocks, so it is good validation to see them buying a stock you’re researching.

Seres Therapeutics, Inc. (NASDAQ: MCRB) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.

With that in mind, Seres Therapeutics, Inc. (NASDAQ: MCRB) now has a 50-day MA of $10.19 and 200-day MA of $15.00. It has traded in a 52-week range between $8.05 – 35.98 and today’s last price is 70.68%% lower than the 52 week high of $35.98.

Indeed, earnings growth is among the most important things to look at in regards to stock investing and, accordingly, investors seek companies that have been successful at growing their earnings at least 25% or more for the past 3 years.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Latest News

Leave a Reply